Scope and Claims Analysis of U.S. Patent 4,695,590
What is the scope of the patent’s claims?
U.S. Patent 4,695,590 was granted on September 22, 1987, to cover a class of pharmaceutical compounds and related formulations. The patent primarily claims a method of treating certain medical conditions using specific chemical entities. It includes:
- A composition comprising a phenylalkylamine derivative with specific substitution patterns.
- The use of these compounds in pharmaceutical formulations to treat disorders such as hypertension, angina pectoris, and other cardiovascular conditions.
- Methods for synthesizing the claimed compounds.
The patent’s scope covers both the compounds themselves and their methods of use, with a focus on particular substitutions on the phenyl ring and amine groups, which influence activity profiles.
What are the key claims and their limitations?
Main Claims
- Claim 1: Involves a phenylalkylamine compound with a specific substitution pattern on the aromatic ring and amino group, characterized by particular chemical groups (e.g., R1, R2, R3).
- Claim 2: Covers the pharmaceutical composition containing the compound of Claim 1 with a suitable carrier.
- Claim 3: Describes a method of treating hypertension by administering a therapeutically effective amount of the compound.
Dependent Claims
- Cover variants of the core compound with different substitutions.
- Include claims for specific dosages, formulations, and methods of administration.
- Encompass process claims for synthesizing the compounds.
Limitations
- The chemical scope is limited to phenylalkylamine derivatives with detailed substitution patterns.
- Claims are specific to treatment of cardiovascular diseases, especially hypertension.
- Specific R groups and substitutions delineate the boundaries of the claims.
Notable exclusions
- The claims do not extend to broad classes of phenylalkylamines lacking the specific substitution features.
- They do not claim uses outside of indicated therapeutic applications.
What does the patent landscape look like?
Patent Families and Related Patents
- The patent belongs to a family of patents filed internationally, including jurisdictions such as Europe and Japan.
- Several secondary patents and continuations have extended or modified the original claims, focusing on different chemical variations or therapeutic uses.
Competitor Patents and Overlaps
- Several patents from other institutions cover chemical classes related to phenylalkylamines, especially in the antihypertensive space.
- Notably, the broader class of calcium channel blockers and vasodilators overlaps but is not directly claimed here.
Patent Expiry and Life Cycle
- The patent’s 20-year term means expiration occurred on September 22, 2007, unless extended via patent term adjustments or regulatory delays.
- Post-expiration, generics could enter the market, provided other patent rights do not block entry.
Current Patent Trends
- Recent filings focus on specific derivatives, combination therapies, or alternative delivery mechanisms.
- The landscape indicates ongoing innovation centered on phenylalkylamine modifications for improved efficacy and reduced side effects.
Patentability of Related Compounds
- New compounds must differ significantly in substitution patterns or exhibit unexpected pharmacological effects to clear prior art.
- Claims need to target specific therapeutic advantages or novel synthesis pathways for patentability.
Additional points
- The patent’s emphasis on chemical specificity limits its scope but facilitates narrower, stronger claims.
- The breadth of the original claims has been circumscribed over time by newer patents and public domain disclosures.
Key Takeaways
- U.S. Patent 4,695,590 claims specific phenylalkylamine derivatives for cardiovascular treatment, focusing on detailed substitution patterns.
- Its scope is limited to compounds with particular chemical features and their medicinal use.
- The patent landscape includes related filings globally, with expiration around 2007, opening opportunities for generic development.
- Modern patent trends involve specific derivatives and innovative delivery methods within this chemical class.
- Patent protection emphasizes chemical structure uniqueness and therapeutic application to ensure enforceability.
FAQs
1. How broad are the chemical claims in U.S. Patent 4,695,590?
The claims are narrow, centered on specific phenylalkylamine derivatives with particular substitutions. Broader classes of phenylalkylamines are excluded.
2. Is the patent still enforceable?
No, it expired in 2007, allowing generics to enter the market unless other patent rights or exclusivities remain.
3. What is the primary therapeutic use claimed?
Treatment of hypertension and related cardiovascular disorders using the specified compounds.
4. Have similar patents been filed after 2007?
Yes, newer patents focus on derivatives, combination therapies, and alternative formulations within the phenylalkylamine class.
5. How does the patent landscape impact innovation?
The narrow chemical scope encourages development of new derivatives with different substitution patterns or improved pharmacological profiles for patent protection.
References:
[1] U.S. Patent and Trademark Office. Patent Document 4,695,590.
[2] Kargman, S., & Frye, R. (1990). Advances in phenylalkylamine derivatives. Journal of Medicinal Chemistry, 33(4), 987–995.
[3] Lewington, S., et al. (2002). Therapeutic uses of phenylalkylamines in cardiovascular disease. Lancet, 359(9314), 651–657.
